Top 10 EAU Guidelines Updates Every FRCS Candidate Must Know in 2025

Essential reading for FRCS Urology Part 1 preparation

Introduction

The European Association of Urology released major guideline updates in March 2025, covering several key areas that frequently appear in the FRCS examination. Understanding these changes is crucial for exam success, as questions often test knowledge of current best-practice recommendations. This article highlights the most important updates you need to know.

1. Upper Urinary Tract Urothelial Carcinoma (UTUC): Complete Revision

What’s New?

The 2025 UTUC guidelines underwent significant changes, making this a high-yield topic for the exam.

Key Updates:

Diagnosis: Significant changes to diagnostic recommendations, emphasising the role of ureteroscopy with biopsy for risk stratification
Risk Stratification: Complete revision of the risk classification system to better predict outcomes
Ureteroscopy Approach: Updated technical recommendations for diagnostic and therapeutic ureteroscopy
Radical Nephroureterectomy: New surgical approach recommendations, including extent of ureteric resection and bladder cuff management
Kidney-Sparing Management: Two new recommendations for localised low-risk UTUC, expanding conservative treatment options
High-Risk Non-Metastatic Disease: Two new recommendations for adjuvant treatment strategies
Follow-up Protocols: Review and adaptation of surveillance schedules based on risk groups
Quality Indicators: New section addressing quality metrics for UTUC management

Exam Relevance

Expect questions on risk stratification criteria, indications for kidney-sparing surgery, and appropriate follow-up protocols. The distinction between low-risk and high-risk disease is crucial.

2. Muscle-Invasive and Metastatic Bladder Cancer: Targeted Therapy Updates

What’s New?

The 2025 guidelines introduced important changes in both localised and metastatic disease management.

Key Updates:

Erdafitinib in Metastatic Disease: New recommendation for using FGFR3 alterations to select patients with unresectable or metastatic urothelial carcinoma for erdafitinib treatment
Radiotherapy Approaches: Significant update to pre- and postoperative radiotherapy recommendations
Sexual Organ Preservation in Women: New recommendations for organ-preserving techniques
Lymph Node Dissection: Updated recommendation on extent of LND based on the SWOG trial results
Hospital Volume Effects: New recommendation acknowledging the impact of surgical volume on outcomes
Trimodality Therapy: New recommendations for salvage cystectomy after bladder-preserving treatment
Multidisciplinary Team Approach: Emphasis on shared decision-making for candidates for trimodality treatment
Adjuvant Nivolumab: Updated recommendation for selected patients with pT3/4 and/or pN+ disease not eligible for or who declined adjuvant chemotherapy

Exam Relevance

Questions may focus on selecting appropriate candidates for targeted therapy, understanding the role of molecular testing, and knowing when trimodality therapy is appropriate versus immediate cystectomy.

3. Renal Cell Carcinoma: Systemic Therapy and SBRT Advances

What’s New?

The RCC guidelines saw updates across diagnosis, staging, and treatment modalities.

Key Updates:

Stereotactic Body Radiotherapy (SBRT): New recommendations for SBRT in localised RCC, particularly for patients unfit for surgery
Adjuvant Therapy: Updated guidance on pembrolizumab use post-nephrectomy in high-risk clear cell RCC
Systemic Therapy for Later Lines: New recommendations for subsequent-line therapy in metastatic clear cell RCC
Non-Clear Cell Subtypes: Enhanced recommendations for managing rare histological subtypes
Hereditary RCC: New dedicated chapter addressing genetic syndromes and surveillance protocols
Partial Nephrectomy Indications: Reinforcement of nephron-sparing surgery whenever technically feasible
WHO 2022 Classification: Integration of the latest histopathological classification system

Exam Relevance

Focus on indications for partial versus radical nephrectomy, understanding the role of adjuvant therapy, and knowing treatment algorithms for metastatic disease by histological subtype.

4. Prostate Cancer: Risk Stratification Refinement

What’s New?

The 2025 prostate cancer guidelines introduced important changes in risk classification and staging.

Key Updates:

Familial and Hereditary PCa: New table defining familial versus hereditary prostate cancer with specific criteria
EAU Risk Groups Revision: The intermediate-risk group has been split into favourable and unfavourable categories for biochemical recurrence
PSA Assessment: New table addressing sources of error in PSA value assessment
MRI in Screening: Significant update to the role of MRI in population-based screening protocols
Transperineal Biopsy: Adaptation of recommendation favouring transperineal approach
N-Staging Surgical Techniques: Restructure and update of surgical approaches for lymph node staging
PSMA PET/CT Staging: Updated recommendation for use in intermediate-risk PCa staging
Quality of Life in ADT: Expansion of the section on androgen deprivation therapy effects and management

Exam Relevance

The split of intermediate-risk into favourable and unfavourable is crucial for treatment selection questions. Know the criteria for genetic testing and the role of PSMA PET/CT in staging different risk groups.

5. Urological Infections: New UTI Classification System

What’s New?

The urological infections guidelines underwent major restructuring in 2025.

Key Updates:

New UTI Classification System: Complete revision of how UTIs are categorised, replacing older classification schemes
Cystitis Management: Updates to Section 3.4 with refined diagnostic and treatment algorithms
Antimicrobial Stewardship: Enhanced emphasis on appropriate antibiotic selection and duration
Complicated vs Uncomplicated UTI: Clarification of definitions and management pathways
Recurrent UTI in Women: Updated guidance on investigation and prophylaxis strategies
Catheter-Associated UTI: New recommendations for prevention and management

Exam Relevance

Understanding the new classification system is essential. Questions may test knowledge of when to investigate further versus treat empirically, and appropriate antibiotic choices based on local resistance patterns.

6. Paediatric Urology: Minimally Invasive Approaches

What’s New?

The paediatric guidelines emphasised modern surgical techniques and renal preservation.

Key Updates:

Minimally Invasive Surgery: Growing emphasis on laparoscopic and robotic-assisted procedures for paediatric conditions
Renal Failure Management: Recommendations for appropriate referral timing for transplantation or dialysis
VUR Management: Updated guidance on which children require surgical intervention versus surveillance
Hypospadias Repair: Refinement of techniques and timing recommendations
Undescended Testis: Clarification of optimal timing for orchidopexy
Neurogenic Bladder in Children: Enhanced protocols for catheterisation and surveillance

Exam Relevance

Know the indications for intervention in paediatric conditions, particularly timing of surgery and when conservative management is appropriate.

7. Urolithiasis: Risk Assessment and Genetic Testing

What’s New?

The stone disease guidelines integrated advanced diagnostic approaches.

Key Updates:

Imaging Algorithms: Ultrasound as first-line, with low-dose CT as the gold standard for precise assessment
Stone Composition Analysis: Enhanced emphasis on compositional analysis guiding treatment and prevention
Genetic Testing: New recommendations for identifying hereditary stone-forming conditions
Medical Expulsive Therapy (MET): Updated evidence-based guidance on alpha-blocker use
Metabolic Work-up: Refined protocols for identifying underlying metabolic abnormalities
Size and Location Thresholds: Treatment algorithms based on stone burden and anatomical location
Preventive Strategies: Individualised prevention based on stone composition and metabolic risk factors

Exam Relevance

Focus on which patients require metabolic work-up, treatment thresholds by stone size and location, and understanding the evidence for MET.

8. Male Sexual and Reproductive Health: Updated Management Strategies

What’s New?

This guideline area saw comprehensive updates in 2025.

Key Updates:

Erectile Dysfunction: Integration of newer phosphodiesterase-5 inhibitors and alternative therapies
Testosterone Deficiency: Refined diagnostic criteria and treatment monitoring protocols
Male Infertility: Updated WHO reference values and investigation pathways
Peyronie’s Disease: New recommendations for conservative and surgical management
Premature Ejaculation: Enhanced treatment algorithms including pharmacological and behavioural approaches

Exam Relevance

Know the diagnostic criteria for hypogonadism, appropriate investigations for infertility, and management options for erectile dysfunction in different patient populations.

9. Integration of PSMA PET/CT Across Guidelines

Cross-Guideline Update

Multiple 2025 guidelines incorporated expanded roles for PSMA PET/CT imaging.

Key Applications:

Prostate Cancer Staging: Now recommended for intermediate-risk disease in addition to high-risk
Biochemical Recurrence: Enhanced role in detecting recurrence at lower PSA levels
Treatment Planning: Integration into radiotherapy planning and surgical decision-making
Detection of Oligometastatic Disease: Identifying candidates for metastasis-directed therapy
UTUC and Bladder Cancer: Emerging role in select cases for nodal staging

Exam Relevance

Understand when PSMA PET/CT changes management compared to conventional imaging. Know its limitations and false-positive rates.

10. Multidisciplinary Team (MDT) Approaches and Shared Decision-Making

Conceptual Update Across All Guidelines

The 2025 guidelines universally emphasised patient-centred care.

Key Themes:

MDT Recommendations: Stronger emphasis on multidisciplinary discussion for complex cases
Shared Decision-Making: Integration of patient preferences and values in treatment selection
Quality Indicators: New metrics for measuring guideline adherence and outcomes
Patient Information: Enhanced focus on providing comprehensive, understandable information
Risk Communication: Improved frameworks for discussing treatment benefits and harms

Exam Relevance

While less directly tested, understanding the principles of shared decision-making may appear in communication and ethics-based scenarios.

How to Use This Information for FRCS Preparation

Study Strategy

Focus on Changes: Exam questions often test recent guideline updates rather than long-established practice
Understand Rationale: Know why recommendations changed, not just what changed
Compare Guidelines: Where NICE and EAU differ, understand both perspectives
Risk Stratification: Many updates involve refined risk classification systems
Evidence Levels: Understand the strength of recommendations (strong vs weak)

High-Yield Areas for Part 1

UTUC risk stratification and management algorithms
Prostate cancer intermediate-risk subdivision
RCC systemic therapy options by line and histology
Bladder cancer molecular markers for treatment selection
Stone disease treatment thresholds
UTI classification and appropriate antibiotic use

Integration with NICE Guidelines

Remember that FRCS exams may reference both EAU and NICE guidelines. Key differences to know:

Treatment availability and cost-effectiveness considerations in NHS
Investigation pathways may differ (e.g., MRI before biopsy in prostate cancer)
Follow-up protocols adapted for UK healthcare structure

Conclusion

The 2025 EAU guideline updates reflect significant advances in urological care, particularly in oncology, imaging technology, and personalised medicine. For FRCS candidates, these updates represent core knowledge that will likely be tested.

Key Takeaways:

UTUC underwent the most extensive revision
Molecular markers are increasingly important in treatment selection
Risk stratification systems have been refined across multiple guidelines
PSMA PET/CT has expanded indications
Patient-centred care and MDT approaches are emphasised throughout

Next Steps:

Download the full guidelines from uroweb.org
Review the summary of changes for each relevant guideline
Create flashcards for new risk stratification criteria
Practice questions that integrate guideline knowledge with clinical scenarios
Stay updated throughout 2025 as guidelines are published

Remember: Guidelines provide a framework for best practice, but clinical judgement remains essential. The exam will test your ability to apply guidelines appropriately to different clinical scenarios.

Further Resources:

EAU Guidelines: https://uroweb.org/guidelines
NICE Urology Guidelines: https://www.nice.org.uk/guidance/conditions-and-diseases/urological-conditions
BAUS Guidance: https://www.baus.org.uk

This article is designed as a study aid for the FRCS Urology Part 1 examination. Always refer to the complete, official guideline documents for comprehensive information.